Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567023131> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2567023131 abstract "INTRODUCTION: Conventional treatment strategies for Temozolomide (TMZ)-resistant high-grade gliomas have been uniformly dismal. We have shown that TMZ-resistant tumors up-regulate stress-associated NKG2D ligands (NKG2DL) during the first hours after exposure to TMZ, thereby creating an opportunity for NKG2DL-directed cell therapies. We report improved survival using a combination of TMZ chemotherapy and gene modified TMZ-resistant γΔ T cells which we term Drug Resistant Immunotherapy (DRI). TMZ resistance is conferred by lentivector transfer of methylguanine methyltransferase (MGMT) enabling cytotoxic lymphocyte function during high-dose chemotherapy.METHODS: Tumor NKG2DL expression and DRI cytotoxicity were assessed by flow cytometry. Intracranial (IC) glioma xenografts were established on Day 0 with either unmodified (P) or a TMZ resistant clone (T) of human primary GBM-X12 passaged exclusively in immunodeficient mice. Tumor-bearing mice were treated with intraperitoneal TMZ 60mg/kg on days 6, 8,13, and 15 followed by IC injection of 1.5 × 106 DRI 4h after each TMZ dose × 2 weeks. Control mice received non-modified cells, TMZ, or no therapy. Survival was assessed using Kaplan-Meier analysis.RESULTS: Both GBM-X12P and X12T express NKG2DL MIC-A, MIC-B, and ULBP-4. DRI cells killed both tumors in vitro at approximately 80% at an effector: target ratio of 20:1 with no toxicity against cultured human astrocytes. Cell therapy alone did not improve survival beyond that of untreated mice. For the parent tumor X12P (Figure 1), TMZ therapy significantly improved median survival over untreated controls (29 vs. 59 days, p < 0.0001), and addition of DRI increased median survival to 120 days with 80% long term survivors. For the TMZ-resistant X12T (Figure 2), TMZ alone did not improve survival over untreated controls (22 vs. 27 days p = 0.4827). Addition of DRI significantly increased median survival from 22 days to 38 days (p = 0.0004) with 10% of animals surviving to day +119. View Large Image | Download PowerPoint Slide View Large Image | Download PowerPoint SlideCONCLUSIONS: This is the first report of combined TMZ chemotherapy and drug-resistance modified γΔ T cell therapy resulting in a significant increase in time to progression and improvement in median and overall survival in immunodeficient mice bearing otherwise impervious human primary xenograft tumors using a strategy is readily adaptable to the clinical setting" @default.
- W2567023131 created "2017-01-06" @default.
- W2567023131 creator A5005110020 @default.
- W2567023131 creator A5005886958 @default.
- W2567023131 creator A5017058575 @default.
- W2567023131 creator A5042038442 @default.
- W2567023131 creator A5086198464 @default.
- W2567023131 creator A5087072662 @default.
- W2567023131 date "2015-05-01" @default.
- W2567023131 modified "2023-09-24" @default.
- W2567023131 title "287. Improved Outcomes Following Drug-Resistant Immunotherapy in a Human Xenograft Model of Temozolomide-Resistant Glioblastoma Multiforme" @default.
- W2567023131 doi "https://doi.org/10.1016/s1525-0016(16)33896-5" @default.
- W2567023131 hasPublicationYear "2015" @default.
- W2567023131 type Work @default.
- W2567023131 sameAs 2567023131 @default.
- W2567023131 citedByCount "0" @default.
- W2567023131 crossrefType "journal-article" @default.
- W2567023131 hasAuthorship W2567023131A5005110020 @default.
- W2567023131 hasAuthorship W2567023131A5005886958 @default.
- W2567023131 hasAuthorship W2567023131A5017058575 @default.
- W2567023131 hasAuthorship W2567023131A5042038442 @default.
- W2567023131 hasAuthorship W2567023131A5086198464 @default.
- W2567023131 hasAuthorship W2567023131A5087072662 @default.
- W2567023131 hasBestOaLocation W25670231311 @default.
- W2567023131 hasConcept C114851261 @default.
- W2567023131 hasConcept C121608353 @default.
- W2567023131 hasConcept C126322002 @default.
- W2567023131 hasConcept C143998085 @default.
- W2567023131 hasConcept C154317977 @default.
- W2567023131 hasConcept C202751555 @default.
- W2567023131 hasConcept C203014093 @default.
- W2567023131 hasConcept C2776694085 @default.
- W2567023131 hasConcept C2777389519 @default.
- W2567023131 hasConcept C2777658100 @default.
- W2567023131 hasConcept C2777701055 @default.
- W2567023131 hasConcept C2778227246 @default.
- W2567023131 hasConcept C2780964509 @default.
- W2567023131 hasConcept C502942594 @default.
- W2567023131 hasConcept C55493867 @default.
- W2567023131 hasConcept C71924100 @default.
- W2567023131 hasConcept C86803240 @default.
- W2567023131 hasConcept C89423630 @default.
- W2567023131 hasConcept C98274493 @default.
- W2567023131 hasConceptScore W2567023131C114851261 @default.
- W2567023131 hasConceptScore W2567023131C121608353 @default.
- W2567023131 hasConceptScore W2567023131C126322002 @default.
- W2567023131 hasConceptScore W2567023131C143998085 @default.
- W2567023131 hasConceptScore W2567023131C154317977 @default.
- W2567023131 hasConceptScore W2567023131C202751555 @default.
- W2567023131 hasConceptScore W2567023131C203014093 @default.
- W2567023131 hasConceptScore W2567023131C2776694085 @default.
- W2567023131 hasConceptScore W2567023131C2777389519 @default.
- W2567023131 hasConceptScore W2567023131C2777658100 @default.
- W2567023131 hasConceptScore W2567023131C2777701055 @default.
- W2567023131 hasConceptScore W2567023131C2778227246 @default.
- W2567023131 hasConceptScore W2567023131C2780964509 @default.
- W2567023131 hasConceptScore W2567023131C502942594 @default.
- W2567023131 hasConceptScore W2567023131C55493867 @default.
- W2567023131 hasConceptScore W2567023131C71924100 @default.
- W2567023131 hasConceptScore W2567023131C86803240 @default.
- W2567023131 hasConceptScore W2567023131C89423630 @default.
- W2567023131 hasConceptScore W2567023131C98274493 @default.
- W2567023131 hasLocation W25670231311 @default.
- W2567023131 hasOpenAccess W2567023131 @default.
- W2567023131 hasPrimaryLocation W25670231311 @default.
- W2567023131 hasRelatedWork W1150253869 @default.
- W2567023131 hasRelatedWork W1591852483 @default.
- W2567023131 hasRelatedWork W1977913972 @default.
- W2567023131 hasRelatedWork W2024589556 @default.
- W2567023131 hasRelatedWork W2047948621 @default.
- W2567023131 hasRelatedWork W2086638351 @default.
- W2567023131 hasRelatedWork W2188672435 @default.
- W2567023131 hasRelatedWork W2277177485 @default.
- W2567023131 hasRelatedWork W2342264104 @default.
- W2567023131 hasRelatedWork W2403271368 @default.
- W2567023131 hasRelatedWork W2561479353 @default.
- W2567023131 hasRelatedWork W2585169823 @default.
- W2567023131 hasRelatedWork W2621323879 @default.
- W2567023131 hasRelatedWork W2896644327 @default.
- W2567023131 hasRelatedWork W2897368980 @default.
- W2567023131 hasRelatedWork W2987687536 @default.
- W2567023131 hasRelatedWork W3025573180 @default.
- W2567023131 hasRelatedWork W3137934273 @default.
- W2567023131 hasRelatedWork W564297314 @default.
- W2567023131 hasRelatedWork W819074335 @default.
- W2567023131 isParatext "false" @default.
- W2567023131 isRetracted "false" @default.
- W2567023131 magId "2567023131" @default.
- W2567023131 workType "article" @default.